Amgen Inc.
Revenue Breakdown
| Fiscal Year | Repatha | EVENITY | Prolia | TEPEZZA | KRYSTEXXA | UPLIZNA | TAVNEOS | Ultra-Rare products | TEZSPIRE | Otezla | Enbrel | AMJEVITA/AMGEVITA | BLINCYTO | Vectibix | KYPROLIS | LUMAKRAS/LUMYKRAS | XGEVA | Nplate | IMDELLTRA | MVASI | EPOGEN | Aranesp | Parsabiv | Neulasta | NEUPOGEN | Sensipar/Mimpara | Other products | Other revenues |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2024 | $2.22B | $1.56B | $4.37B | $1.85B | $1.19B | $379.0M | $283.0M | $758.0M | $972.0M | $2.13B | $3.32B | $761.0M | $1.22B | $1.05B | $1.50B | $350.0M | $2.23B | $1.46B | $115.0M | $727.0M | $125.0M | $1.34B | $356.0M | $431.0M | — | — | $1.35B | $1.40B |
| FY2025 | $3.02B | $2.10B | $4.41B | $1.90B | $1.34B | — | — | — | $1.48B | $2.27B | $2.23B | — | $1.56B | $1.18B | $1.41B | — | $2.08B | $1.52B | — | — | — | $1.39B | — | — | — | — | $7.26B | $1.60B |